Comments on 'Sample size for equivalence trials: a case study from a vaccine lot consistency trial' by J. Ganju, A. Izu and A. Anemona.
作者信息
Sun Xiao, Li Xiaoming, Chen Joshua
出版信息
Stat Med. 2012 Jul 10;31(15):1652-3; author reply 1654. doi: 10.1002/sim.4408.
DOI:10.1002/sim.4408
PMID:22711252
Abstract
摘要
相似文献
1
Comments on 'Sample size for equivalence trials: a case study from a vaccine lot consistency trial' by J. Ganju, A. Izu and A. Anemona.
Stat Med. 2012 Jul 10;31(15):1652-3; author reply 1654. doi: 10.1002/sim.4408.
2
Comments on 'Sample size for equivalence trials: A case study from a vaccine lot consistency trial' by J. Ganju, A. Izu and A. Anemona, Statistics in Medicine 2008; 27:3743-3754.
Stat Med. 2009 Jan 15;28(1):177-8, author reply 178-9. doi: 10.1002/sim.3443.
3
Sample size for equivalence trials: a case study from a vaccine lot consistency trial.
Stat Med. 2008 Aug 30;27(19):3743-54. doi: 10.1002/sim.3273.
4
Statistical considerations for vaccine immunogenicity trials. Part 2: Noninferiority and other statistical approaches to vaccine evaluation.
Vaccine. 2005 Feb 18;23(13):1606-14. doi: 10.1016/j.vaccine.2004.06.047.
5
Comments on 'Use of composite endpoints in clinical trials' by Abdul J. Sankoh, Haihong Li and Ralph B. D'Agostino, Sr.
Stat Med. 2016 Jan 30;35(2):317-8. doi: 10.1002/sim.6483.
6
FDA introductory comments: clinical studies design and evaluation issues.
Clin Trials. 2005;2(4):273-5. doi: 10.1191/1740774505cn096oa.
7
Statistical considerations for confirmatory clinical trials for similar biotherapeutic products.
Biologicals. 2011 Sep;39(5):266-9. doi: 10.1016/j.biologicals.2011.06.006. Epub 2011 Jul 31.
8
Journal club 101 for the new practitioner: evaluation of a clinical trial.
Am J Health Syst Pharm. 2004 Sep 15;61(18):1885-7. doi: 10.1093/ajhp/61.18.1885.
9
[Clinical drug trials. 1: The 4 phases of clinical trials].
Fortschr Med. 1991 Feb 20;109(5):136-7.
10
The effect of experimental design parameters on the determination of sample size.
J Periodontal Res. 1992 Jul;27(4 Pt 2):320-2. doi: 10.1111/j.1600-0765.1992.tb01686.x.
引用本文的文献
1
Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine.
Hum Vaccin Immunother. 2015;11(6):1306-12. doi: 10.1080/21645515.2015.1009819.
Zotero 插件